Recursion aligns with FDA on Phase 3 design for REC-4881 in FAP
FROM THE WIRE · GLOBENEWSWIRE.COM
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion's…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA key regulatory step for an AI-discovered program in an indication with no approved therapies.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Recursion reached alignment with the FDA on the registrational Phase 3 design for REC-4881.
- 02The drug targets familial adenomatous polyposis, which has no approved pharmacologic therapies.
- 03The candidate was identified through phenotypic screening using Recursion's AI foundation models.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets